ILiAD Biotechnologies
ILiAD Biotechnologies, Inc. is a privately held, clinical-stage biotechnology company headquartered in Weston, Florida, developing BPZE1 — a live attenuated intranasal vaccine candidate designed to prevent Bordetella pertussis (whooping cough) colonization and transmission — alongside its B-Tech vector platform, which the company is exploring for infectious, allergic, autoimmune and neurodegenerative disease. The BPZE1 technology originated at Institut Pasteur de Lille and is exclusively licensed to ILiAD, which announced a $115M Series B in February 2026 and received a UK MHRA Innovation Passport designation in December 2024. ILiAD publishes a static corporate and scientific website only: as of 2026-08-22 it operates no public API, developer portal, SDK, machine-readable specification, or any other programmable surface.
ILiAD Biotechnologies is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Vaccines, Life Sciences, and Pharmaceuticals.
ILiAD Biotechnologies’ developer surface includes product news and 13 more developer resources.
Kin Score
Privacy & Data 1
Its role, the data it processes, retention and transfers, quoted from its own privacy page.
ILiAD Biotechnologies
21 quoted statements, read from ILiAD Biotechnologies's own page on 2026-11-09.
PRIVACYSecurity Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 5
The organization behind the API
Other 5
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.